MDMA-assisted Therapy Versus Cognitive Processing Therapy for Veterans With Severe Posttraumatic Stress Disorder
This randomized, interventional trial (n=30) will compare MDMA-assisted Cognitive Processing Therapy (three MDMA sessions plus preparatory and integration therapy) versus standard Cognitive Processing Therapy for Veterans with severe PTSD.
Details
Randomized, parallel-group trial comparing MDMA-assisted Cognitive Processing Therapy (MDMA-aCPT) with standard Cognitive Processing Therapy (CPT) in U.S. military Veterans with severe PTSD to assess clinical effectiveness, implementation feasibility, and health economics.
MDMA-aCPT includes one 90-minute preparatory session, three ~8-hour experimental MDMA sessions (initial doses 80 mg with optional supplemental doses; later sessions 80 or 120 mg with optional supplements), and three 90-minute integration sessions, alongside 8–15 CPT sessions (average 12).
Outcomes include PTSD symptom reduction, feasibility and implementation metrics within the VA system, and economic assessments to inform potential deployment of MDMA-aCPT in VA settings.